Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle the Impacts of Non-Communicable Diseases
Shots:
- The Defeat-NCD Partnership and BI partnered to address the access to healthcare issues related to NCDs by helping governments to strengthen national institutions- scaling up community-based health services and expanding the accessible range of medicines and healthcare solutions
- The focus of the collaboration is to tackle premature death- sickness- disability- and associated social and economic impacts from NCDs in low resources countries
- BI’s portfolio contains 85% therapies targeting NCD and with its Access to Healthcare strategy- based on the three strategic pillars Availability- Innovative Solutions and Sustainable Models to explore & evaluate a holistic approach for broadening healthcare access in underserved communities and countries
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: WestFair
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com